Efficacy of imatinib for the treatment of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis

Efficacy of imatinib for the treatment of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis - Efficacy of imatinib for the treatment of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020543

Enrollment

Registered

2016-01-13

Start date

2015-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis

Interventions

Oral administration of imatinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are diagnosed with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis and treated at the principal investigator's institution Patients who are 18 years or older at the time of giving their written consent

Exclusion criteria

Exclusion criteria: Patients with a contraindication to imatinib Patients who were considered as inadequate for enrollment by the principal investigator

Design outcomes

Primary

Measure	Time frame
Efficacy (Time to clinical worsening)	—

Secondary

Measure	Time frame
Safety Efficacy (Median survival)	—

Countries

Japan

Contacts

Public ContactHiromi Matsubara

National Hospital Organization Okayama Medical Center Departments of Cardiology and Clinical Science

himatsu@okayamamc.jp086-294-9911

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026